Sentiment · CI

Lobbying Spend for CI

AI-generated plain-English read of lobbying spend for CI. Updated daily.

Heavy and rising. The company is building a more serious DC presence quarter over quarter — watch for a policy catalyst that would explain the ramp.

What will probably happen

A rising trend without an obvious single catalyst suggests broadening DC engagement — a structural shift, not a one-quarter reaction.
Issue concentration is high (MEDICARE/MEDICAID dominates). The policy outcome of that specific area will drive whether this spend was effective.

If you HOLD this stock: Deepening DC engagement — hold your position but monitor the primary issue area for policy news that could catalyze a move in either direction.
If you're EVALUATING this stock: Heavy DC presence is a recurring cost and risk factor — factor in the regulatory environment when sizing. Requires research into the primary issue areas.
If you trade OPTIONS: No clean options signal derived from this lobbying read.

10 quarters of history with $30.44M in total spend — sufficient data for a reliable trajectory read.

Technical details

Spend tier: Heavy
Trajectory: Rising
Last quarter: $3.24M
Last 4Q total: $13.87M
Prior 4Q total: $12.03M
Top issue area: MEDICARE/MEDICAID (67% of spend)
Top registrant: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) (84% of spend)
Registrant base: In house
Quarters on record: 10
Unique issue areas: 5
Unique registrants: 11
Issue concentration: Laser focused

Lobbying disclosures are quarterly and reflect activity already past. The signal is structural, not timing.
A single issue area dominates spend (MEDICARE/MEDICAID, 67%). Read the policy implication of THAT specific issue rather than the aggregate dollar number.
The primary registrant appears to be an in-house government-affairs operation. In-house lobbying may not be captured in full by third-party disclosure data.